In a report released today, Steven Lichtman from Oppenheimer maintained a Buy rating on Integra Lifesciences (NASDAQ: IART). The company’s shares closed yesterday at $64.51, close to its 52-week high of $67.50.
According to TipRanks.com, Lichtman has 0 stars on 0-5 star ranking scale with an average return of -3.5% and a 53.1% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Motus Gi Holdings Inc.
Integra Lifesciences has an analyst consensus of Hold, with a price target consensus of $65.60.
See today’s analyst top recommended stocks >>
Integra Lifesciences’ market cap is currently $5.48B and has a P/E ratio of 73.31. The company has a Price to Book ratio of 4.08.
Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Orthopedics and Tissue Technologies segments.
